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Abstract Converging lines of evidence suggest that
AKT1 is a major mediator of the responses to insulin,
insulin-like growth factor 1 (IGF1), and glucose. AKT1
also plays a key role in the regulation of both muscle cell
hypertrophy and atrophy. We hypothesized that AKT1
variants may play a role in the endophenotypes that make
up metabolic syndrome. We studied a 12-kb region
including the ﬁrst exon of the AKT1 gene for association
with metabolic syndrome-related phenotypes in four study
populations [FAMUSS cohort (n = 574; age 23.7 ±
5.7 years), Strong Heart Study (SHS) (n = 2,134; age
55.5 ± 7.9 years), Dynamics of Health, Aging and Body
Composition (Health ABC) (n = 3,075; age 73.6 ±
2.9 years), and Studies of a Targeted Risk Reduction
Intervention through Deﬁned Exercise (STRRIDE)
(n = 175; age 40–65 years)]. We identiﬁed a three SNP
haplotype that we call H1, which represents the ancestral
alleles at the three loci and H2, which represents the
derived alleles at the three loci. In young adult European
Americans (FAMUSS), H1 was associated with higher
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DOI 10.1007/s00439-010-0910-8fasting glucose levels in females. In middle age Native
Americans (SHS), H1 carriers showed higher fasting
insulin and HOMA in males, and higher BMI in females. In
older African-American and European American subjects
(Health ABC) H1 carriers showed a higher incidence of
metabolic syndrome. Homozygotes for the H1 haplotype
showed about twice the risk of metabolic syndrome in both
males and females (p\0.001). In middle-aged European
Americans with insulin resistance (STRRIDE) studied by
intravenous glucose tolerance test (IVGTT), H1 carriers
showed increased insulin resistance due to the Sg compo-
nent (p = 0.021). The 12-kb haplotype is a risk factor for
metabolic syndrome and insulin resistance that needs to be
explored in further populations.
Introduction
AKT1 [also called protein kinase B (PKB)] is involved in
two major signaling pathways: the regulation of muscle
hypertrophy and atrophy (Nader 2005) and AKT1 is
mediator of the biological functions of insulin and aug-
ments glucose uptake in muscle, adipocytes and liver along
with a host of other tissues (Elghazi et al. 2006; Zdychova
and Komers 2005). AKT1 mediates glucose uptake by
inducing translocation of vesicles containing GLUT4 from
intracellular stores to the plasma membrane (Hajduch et al.
1998). Brieﬂy, upon insulin stimulation, AKT1 agonists
activate receptor kinase functions that result in the stimu-
lation of tyrosine phosphorylation of substrates such as
IRS1 (Sun et al. 1991) and IRS2 (Sun et al. 1995). Tyrosyl
phosphorylation of the IRSs provides binding sites for
speciﬁc proteins containing Src-homology 2 (SH2)
domains such as PI3K. PI3K is responsible for the insulin
stimulation of GLUT4, the major insulin-regulated glucose
transporter from intracellular vesicles to the plasma
membrane in insulin-sensitive cells (Frevert et al. 1998).
In order to look at the function of AKT1 in pancreatic
beta cells, researchers over-expressed constitutively active
AKT1 in the b-cells of mice resulting in augmented b-cell
mass by an increase in proliferation and cell size (Bernal-
Mizrachi et al. 2001; Tuttle et al. 2001), and resistance to
streptozotocin-induced diabetes (Bernal-Mizrachi et al.
2001; Tuttle et al. 2001). Mice with reduced Akt/Pkb
activity in b-cells exhibited normal b-cell mass but
defective insulin secretion (Bernal-Mizrachi et al. 2004),
and increased susceptibility to developing glucose intoler-
ance and diabetes following fat feeding (Bernal-Mizrachi
et al. 2004). The roles of AKT1 as a key mediator in both
muscle hypertrophy and atrophy and insulin signaling and
glucose uptake indicate that this gene may play a role in a
metabolic phenotypes, speciﬁcally the endophenotypes that
together lead to metabolic syndrome.
Thus, we studied the AKT1 gene as a candidate for
metabolic syndrome features. We hypothesized that the use
of a young adult population would increase sensitivity for
detection of these phenotypes, as all are well-documented
to be age-related. Further, each phenotype has many
potential environmental inﬂuences (lifestyle, training, diet),
thus we hypothesize that a college-age population might
have fewer potential confounders (Thompson et al. 2004;
Uthurralt et al. 2007; Zoeller et al. 2007).
Here, we report the AKT1 haplotype structure, including
a relatively small region of 12 kb with two predominant
haplotypes (H1 and H2) upstream and inclusive of the ﬁrst
exon of the AKT1 gene. We evaluated a hap-tag SNP
(rs1130214) in three population-based cohorts (FAMUSS,
SHS, Health ABC), and one cohort focused on insulin
resistance and response to training (STRRIDE) (Harris
et al. 2005; Lee et al. 1990; Slentz et al. 2007; Thompson
et al. 2004). We show that the H1 12 kb AKT1 haplotype is
signiﬁcantly associated with higher fasting serum glucose
levels, and an increased risk for developing metabolic
syndrome.
Participants and methods
Subject populations
FAMUSS population
The study design of the FAMUSS Study has been reported
(Thompson et al. 2004). Brieﬂy, 574 volunteers
(18–41 years; mean 23.7 ± 5.7) were enrolled into a uni-
lateral supervised 12-week resistance training intervention
of the non-dominant arm. Quantiﬁed phenotypes included
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123baseline blood pressure, height and weight and serum
measurements including HDL, total cholesterol, fasting
glucose, fasting insulin, and triglycerides. A dichotomous
characterization of metabolic syndrome was deﬁned as
fulﬁlling at least three of the ﬁve criteria proposed by
NCEP (2001). These criteria include an elevated waist
circumference, triglycerides, blood pressure, fasting glu-
cose and reduced HDL cholesterol. Because the FAMUSS
Study did not collect waist circumference measurements,
an elevated BMI ([25) was used as a surrogate.
Strong Heart Study
The SHS is a study of CVD and its risk factors among
American Indian men and women (Lee et al. 1990).
Brieﬂy, DNA and serum measurements were collected on
2,134 volunteers (45–75 years; mean 55.5 ± 7.9). Quan-
tiﬁed phenotypes included baseline blood pressure, height
and weight and serum measurements including HDL, total
cholesterol, fasting glucose, fasting insulin, triglycerides
and incidence of metabolic syndrome.
Health ABC Study
Health ABC is a longitudinal study of body composition in
older men and women with goals of identifying the clinical
conditions that accelerate changes in and examining the
health impact of these changes on the diseases of old age
(Visser et al. 1999). Brieﬂy, DNA and serum measure-
ments were collected on 3,075 volunteers (68–80 years;
mean 73.6 ± 2.9). Quantiﬁed phenotypes included base-
line blood pressure, height and weight and serum mea-
surements including HDL, total cholesterol, fasting glucose
and fasting insulin. Triglycerides and incidence of meta-
bolic syndrome and diabetes were classiﬁed as dichoto-
mous phenotypes using NCEP ATP III criteria.
STRRIDE Study
The STRRIDE Study is a controlled study designed to
measure the effect of exercise on abdominal fat. Brieﬂy,
175 overweight individuals, male and female, aged
40–65 years were assigned an 8-month exercise regimen.
All participants had mild to moderate lipid abnormalities.
They were randomly assigned to one of three exercise
groups: (1) high amount/vigorous intensity (65–80% of
peak oxygen consumption), (2) low amount/vigorous
intensity (65–80% of peak oxygen consumption), and (3)
low amount/moderate intensity (40–55% of peak oxygen
consumption). Quantiﬁed phenotypes included tomography
scans of abdominal fat, BMI measures, Sg (glucose-stimu-
lated glucose-release), insulin sensitivity index (ISI) and
acute insulin response to glucose (AIRg).
Phenotype measures for FAMUSS Study
Serum measurements were made from stored fasting sera
and plasma from each subject (baseline). Measurements:
fasting glucose, fasting insulin, C-reactive protein and lipid
panel (triglycerides and HDL). All measurements were
made by Quest Diagnostics (Chantilly VA).
SNP discovery
SNPs for each exon, exon/intron boundaries, and 10 kb
upstream (50) to the AKT1 gene were identiﬁed by
screening a panel of 96 ethnically diverse genomic DNA
samples with denaturing high performance liquid chroma-
tography (Transgenomic WAVE system, Transgenomic,
USA) and automated sequencing (Applied Biosystems
3100 Genetic Analyzer). Polymorphisms were tested for
allele frequency, and cross-referenced to dbSNP (http://
www.dbSNP.org) and HapMap (http://www.hapmap.org)
data resources. Twelve SNPs were studied in depth,
selected based upon allele frequency and linkage disequi-
librium testing. The published sensitivity of DHPLC for
SNP detection is 96% (Jones et al. 1999). However, to
reach that level of SNP detection requires optimal tem-
perature selection and possibly primer redesign (Jones et al.
1999). For this publication, we cannot be certain that we
did not miss additional variation in the AKT1 regions that
we scanned due to the level of sensitivity of this technique.
In addition, DHPLC suffers from the inability to discover
homozygote changes and would require mixing of a sample
with a known sequence to all scanned samples for the
discovery of homozygous changes (Mogensen et al. 2003).
DHPLC Novel SNPs not in dbSNP or HapMap databases
were submitted to dbSNP. A list of the SNPs studied and
their respective dbSNP identiﬁers (including those sub-
mitted to dbSNP) can be found in Table 1.
Genotyping
Genotyping was done using a novel TaqMan allele dis-
crimination assay that employs the 50 nuclease activity of
Taq polymerase to detect a ﬂuorescent reporter signal
generated during PCR reactions (see Supplemental
Table 1). Both alleles were detected simultaneously using
allele-speciﬁc oligonucleotides labeled with different
ﬂuorophores, and genotypes determined by the ratio of the
two ﬂuorophores used. Allele-speciﬁc PCR reactions for
each SNP included 10 ng genomic DNA, 900 nM forward
and reverse PCR primers, 200 nM ﬂuorescent allele dis-
crimination probes (common allele FAM labeled; rare
allele VIC labeled) and TaqMan
 Universal PCR Master
Mix, No AmpErase
 UNG [Applied Biosystems (ABI),
Foster City, CA, USA] in a ﬁnal volume of 10 ll. The PCR
Hum Genet (2011) 129:129–139 131
123and ﬂuorescent ratio proﬁle was done using 10 min at 95C
(denaturation), and 44 cycles of 15 s at 92C and 1 min at
an annealing temperature of 60C. Reactions were set up
using a MWG robot, and ﬂuorescence ratios and allele
calling done using an ABI 7900.
Linkage disequilibrium
Pair-wise tests for linkage disequilibrium were done for all
12 AKT1 polymorphisms using the correlation coefﬁcient
(R) on each pair-wise combination in the 1,078 FAMUSS
subjects. A haplotype minimization algorithm contained
within the PHASE v 2.1 program (Stephens et al. 2001)
was then used to establish haplotypes from these data.
Statistical methods
Hardy–Weinberg equilibrium was determined for each
SNP using a v
2 test to compare the observed genotype
frequencies to those expected under H–W equilibrium. All
genotyped SNPs were in H–W equilibrium.
All metabolic syndrome-related phenotypes were ana-
lyzed as either continuous quantitative traits (triglycerides,
fasting glucose, etc.) or as dichotomous traits (metabolic
syndrome and high/low triglyceride level). Normality of
each quantitative trait was conﬁrmed using the Shapiro–
Wilk normality test.
Bivariate correlation analyses of each quantitative
measurement showed several signiﬁcant correlations with
age and baseline mass; therefore, associations between
each SNP and quantitative phenotype were assessed using
analysis of covariance (ANCOVA) methods. Due to large
gender differences all analyses were performed separately
for males and females.
Each ANCOVA used a dominant genetic model statis-
tically comparing the group of homozygous wild-type
individuals to the group of heterozygous and homozygous
mutant individuals.
Linear regression analysis, including likelihood ratio
tests between full (containing genotype and covariates) and
constrained (containing covariates only) models, were
performed to estimate the proportion of variance in volu-
metric measurements attributable to each SNP’s genotype.
For dichotomous traits, logistic regression models adjusted
for age and baseline body mass were used. A nominal
p value of 0.05 was deﬁned as signiﬁcant and all statistical
analyses were performed using Stata V.8 (StataCorp,
College Park, TX).
Results
SNP discovery and haplotypes of AKT1
SNPs for each exon, exon/intron boundaries, and 10 kb
upstream (50) to the AKT1 gene (Genbank
NM_001014431.1) were identiﬁed by screening a panel of
96 ethnically diverse genomic DNA samples with dena-
turing high performance liquid chromatography and auto-
mated sequencing. We identiﬁed 12 SNPs in AKT1,7o f
which were intragenic and 5 of which were upstream of the
gene. A list of the SNPs studied and their respective dbSNP
identiﬁers (including three novel SNPs submitted to
dbSNP) can be found in Table 1.
The SNPs were genotyped in the FAMUSS population
(Table 2) to identify regions that showed strong linkage
disequilibrium to test in additional populations. Two major
haplotype blocks were identiﬁed, one including most of the
coding region of the gene and one 12 kb haplotype
upstream of AKT1 inclusive of the ﬁrst exon, haplotype
H1/H2. The H1/H2 haplotype is composed of SNPs:
rs1130214, rs10141867 and rs33925946. The H1 haplotype
alleles are GCC for those three SNPs; the H2 haplotype
alleles are TTA for those three SNPs (on the plus strand
DNA). LD plots were generated showing the extent of LD
between the SNPs listed in Table 1. The SNPs of haplotype
H1/H2 are shown in red text. The amount of LD between
Table 1 AKT1 single nucleotide polymorphisms discovered using
DHPLC in a 96-individual panel
SNP position in AKT1
a SNP rs#
-C9756A rs33925946 Novel
-C6148T rs4983387
-C6024T rs10141867
-C5854T rs34284721 Novel
-C832G rs2494750
?G1780A rs28634999 Novel
?G2347T rs1130214
?G2375A rs10138227
?A15756T rs2494737
?G20703A rs3730346
?A22889G rs2494732
?G23477A rs2498800
a Numbering based on Genbank NM_001014431.1
Table 2 Characteristics of the FAMUSS cohort
Characteristic Females Males
N Mean ± SD N Mean ± SD
Age (years) 359 23.58 ± 5.62 215 24.29 ± 5.90
Weight (kg) 359 65.3 ± 12.8 215 81.2 ± 17.2
Height (cm) 359 165 ± 6.8 215 177.8 ± 6.8
BMI 359 23.94 ± 4.66 215 25.61 ± 5.15
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123any two SNPs (plotted on the X and Y axis) as determined
by the correlation coefﬁcient R is shown on a color scale
from blue to red. Blue equals r
2 of zero, or no LD; red
equals r
2 of 1 or perfect LD (Fig. 1). SNP rs10138227
shows some LD with the other three but it is not strong
enough to include as part of the haplotype. From this work,
we chose to analyze rs1130214 as a hap-tag SNP repre-
senting a 12 kb haplotype covering the ﬁrst intron/10 kb
upstream.
Associations between AKT1 and the FAMUSS, Strong
Heart Study, Health ABC and STRRIDE studies
We used the young adult FAMUSS population to screen for
associations between the AKT1 gene polymorphisms of the
H1/H2 haplotype and metabolic syndrome endopheno-
types: increased adiposity, increased blood pressure, low
serum HDL, insulin resistance and fasting glucose levels,
with subsequent validation of associations in additional
population-based cohorts (SHS, Health ABC) and in the
insulin resistant population STRRIDE (demographics of
these four populations are shown in Tables 2, 3, 4, 5).
The SNP association analyses were done with both het-
erozygotes(GT)andhomozygotesfortheTallele(TT)inthe
same group because the number of TT individuals was too
low in some groups to see an effect. Therefore, the analyses
are interpretedas associationswith atleast one copyof the T
allele (H2) versus homozygotes for the G allele (H1).
The H1/H2 hap-tag SNP rs1130214 was associated with
fasting glucose only in females and this SNP contributed
1.3% to genotypic variance (Table 6). SNP rs1130214
causes a G to T change (representing the H1 and H2
haplotypes, respectively). With at least one copy of the T
allele, females had lower values of fasting glucose (GG,
N = 201; 86.22 ± 0.50 mg/dL vs. GT/TT, N = 178;
84.55 ± 0.53 mg/dL; p = 0.0236). This SNP did not have
any associations with any metabolic syndrome endophe-
notypes in males in the FAMUSS Study.
Wethenusedrs1130214asahap-tagSNP,andgenotyped
bothStrongHeartStudy(Table 3)andHealthABC(Table 4)
Table 3 Characteristics of the Strong Heart cohort
Characteristic Females (N = 1,349) Males (N = 785)
Tribe
Arizona 724 357
South Dakota 625 428
Age (years) 56.19 ± 7.87 55.45 ± 7.66
Weight (kg) 81.11 ± 17.10 89.37 ± 19.33
Height (cm) 159.47 ± 5.66 173.14 ± 6.35
BMI 31.89 ± 6.52 29.78 ± 6.07
Fig. 1 Linkage disequilibrium
among AKT1 SNPs within the
FAMUSS population and SHS.
Linkage disequilibrium is
plotted for African-Americans,
Asians and European
Americans of the FMS cohort.
The LD was calculated between
each pair of SNPs using the r
2
measurement and haplotype
frequencies were estimated
using the online program
PHASE, which uses genotype
data to determine the phase of
the chromosomes and thus
haplotype structure and
frequency. The SNPs from
Table 1 are plotted on the X and
Y axes. A color scale is then
used to plot the LD between any
two SNPs. Blue equals an r
2 of
zero, red equals an r
2 of 1.0.
The SNPs of H1/H2 are in red
text. All three of the SNPs are in
high LD with each other as
shown by the red blocks
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123to test for any associations with metabolic phenotypes in
older cohorts. For the older and more heterogeneous Strong
Heart Study population of Native Americans, rs1130214
showed association with 2-h glucose, fasting insulin, tri-
glycerides, and the HOMA measure of insulin resistance in
males (Table 7). The T allele was associated with lower 2 h
glucose levels (GG, N = 434; 180.69 ± 5.11 mg/dL vs.
GT/TT, N = 147; 160.01 ± 8.77 mg/dL; p = 0.0422) and
lower fasting insulin (GG, N = 564; 19.44 ± 0.68 lIU/mL
vs. GT/TT, N = 208; 16.21 ± 1.12 lIU/mL; p = 0.0136).
Inaddition,inmales,theTallelewasassociatedwithalower
HOMA value (GG, N = 559; 7.52 ± 0.32 vs. GT/TT,
N = 203; 6.15 ± 0.53; p = 0.267).
In male participants in the Health ABC Study, the T
allele of rs1130214 was associated with lower fasting
glucose (GG, N = 661; 110.5 ± 1.4 mg/dL vs. GT/TT,
N = 798; 106.4 ± 1.3 mg/dL; p = 0.0305) (Table 8).
This effect was also seen in African-Americans males (GG,
N = 205; 116.8 ± 2.9 mg/dL vs. GT/TT, N = 328;
107.7 ± 2.3 mg/dL; p = 0.0170). These results are not
signiﬁcant after correction for multiple testing (p\0.007);
however, the statistical community is divided on correction
methods for multiple testing since the Bonferonni correc-
tion may be too harsh and thus increasing false negatives
(Rice et al. 2008).
Taken together, associations from all three population-
based cohorts suggested that the AKT1 upstream haplotype
was a determinant of insulin resistance, resulting in higher
circulating glucose and/or insulin with apparent age- and
sex-dependence.
Associations between AKT1 rs1130214 and the Health
ABC Study for metabolic syndrome
The ﬁve commonly accepted endophenotypes of metabolic
syndrome are: increased insulin resistance or fasting glu-
cose plasma levels ([100 mg/dl), increased adiposity
(central obesity or BMI[30), elevated triglycerides
(equal to or greater than 150 mg/dL), increased blood
pressure ([130mmHg/85mmHg), and low serum HDL
(\40–50 mg/dl) (Alberti et al. 2006; Alberti and Zimmet
1998; Grundy et al. 2004; NCEP 2001). To determine if the
H1/H2 haplotype is a major determinant of metabolic
syndrome diagnosis, we studied the Health ABC popula-
tion. This population-based study had a diagnosis of T2D
as an exclusion criterion, with excellent phenotyping of
metabolic syndrome endophenotypes in a tightly restricted
age range (Harris et al. 2005).
The incidence of metabolic syndrome showed a signi-
ﬁcant association with rs1130214 in the Health ABC
Table 4 Characteristics of the
Health ABC cohort
Characteristic African-Americans Caucasians
Females
(N = 729)
Males
(N = 552)
Females
(N = 855)
Males
(n = 939)
Site
Memphis 337 276 459 476
Pittsburgh 392 276 396 463
Age (years) 73.37 ± 2.95 73.51 ± 2.78 73.60 ± 2.79 73.92 ± 2.92
Weight (kg) 75.60 ± 15.76 81.44 ± 14.73 66.25 ± 12.21 81.36 ± 12.38
BMI 29.66 ± 5.86 27.18 ± 4.40 26.03 ± 4.54 27.00 ± 3.68
Table 5 Characteristics of the
STRIDDE cohort
Characteristic African-Americans Caucasians
Females (N = 52) Males (N = 32) Females (N = 139) Males (n = 154)
Age (years) 50.17 ± 4.66 49.03 ± 6.18 54.93 ± 5.14 50.44 ± 7.04
Weight (kg) 85.89 ± 12.67 96.74 ± 13.67 78.34 ± 10.75 95.68 ± 12.28
Height (cm) 163.39 ± 6.83 176/02 ± 7.98 163.22 ± 6.19 177.95 ± 5.83
BMI 32.07 ± 3.46 31.20 ± 3.73 29.36 ± 3.25 30.14 ± 2.91
Table 6 Association of the T allele of rs1130214 in FAMUSS with decreased glucose
SNP Phenotype Gender N, adjusted mean ± SEM p value % variation attributable
to genotype
rs1130214 Fasting glucose Female GG (N = 201; 86.22 ± 0.50)
GT/TT (N = 178; 84.55 ± 0.53)
0.0236 1.3%
134 Hum Genet (2011) 129:129–139
123population (Table 9). The analysis was done for both het-
erozygotes (GT) and homozygotes for the T allele (TT)
because the number of TT individuals was too low for
some groups to determine any effect. We saw strong effects
with having at least one copy of the T allele suggesting that
haplotype H2 strongly inﬂuences these phenotypes even in
the presence of one copy of the H1 haplotype (represented
by the G allele). Individuals with at least one copy of the T
allele were much less likely to have metabolic syndrome,
consistentwiththelowerinsulinresistanceobservedwiththe
T allele (H2) in all three cohorts. This was true for the entire
Health ABC cohort (GT/TT: OR = 0.765, p = 0.001) and
all males (GT/TT: OR = 0.650, p\0.001). There was a
signiﬁcant effect in all females for the TT individuals only
(TT, OR = 0.577; p = 0.005). The T allele showed a very
strong protective effect in African-American males (GT,
OR = 0.539; p = 0.007). These results are signiﬁcant after
correction for multiple testing (p\0.007).
Table 9 The T allele of
rs1130214 is protective of
metabolic syndrome in HABC
cohort
Group rs1130214
genotype
N (controls) N (metabolic
syndrome)
Odds
ratio
p value 95% conﬁdence
interval
All subjects GG 812 566 1.00
GT/TT 1,028 586 0.765 0.001 0.655–0.894
All males GG 408 251 1.00
GT/TT 522 244 0.650 \0.001 0.512–0.826
Caucasian males GG 275 179 1.00
GT/TT 300 169 0.849 0.050 0.558–1.000
African-American males GG 133 72 1.00
GT/TT 252 75 0.545 0.005 0.357–0.834
All females GG 404 325 1.00
GT/TT 476 342 0.854 0.151 0.689–1.059
Caucasian females GG 236 186 1.00
GT/TT 244 167 0.804 0.148 0.598–1.080
African-American females GG 168 129 1.00
GT/TT 232 175 0.978 0.894 0.712–1.346
Table 7 Association of the T allele of rs1130214 in SHS with parameters of metabolic syndrome
SNP Phenotype Gender N, adjusted mean ± SEM p value % variation attributable
to genotype
rs1130214 BMI Female GG (N = 1,131; 31.87 ± 0.19) 0.0271 0.3
GT/TT (N = 396; 31.04 ± 0.32)
rs1130214 2 h glucose Male GG (N = 434; 180.69 ± 5.11) 0.0422 0.7
GT/TT (N = 147; 160.01 ± 8.77)
rs1130214 Fasting insulin Male GG (N = 564; 19.44 ± 0.68) 0.0136 0.6
GT/TT (N = 208; 16.21 ± 1.12)
rs1130214 Triglycerides Male GG (N = 565; 142.66 ± 9.92) 0.0141 0.8
GT/TT (N = 208; 189.74 ± 16.35)
rs1130214 HOMA Male GG (N = 559; 7.52 ± 0.32) 0.0267 0.6
GT/TT (N = 203; 6.15 ± 0.53)
Table 8 Association of the T allele of rs1130214 in HABC cohort with decreased fasting glucose
SNP Phenotype Gender/Ethnicity N, Adjusted mean ± SEM p value % variation attributable
to genotype
rs1130214 Fasting glucose All males GG (N = 661; 110.5 ± 1.4)* *p = 0.0305 0.3
GT/TT (N = 798; 106.4 ± 1.3)*
rs1130214 Fasting glucose African-American males GG (N = 205; 116.8 ± 2.9)* *p = 0.0170 1.1
GT/TT (N = 328; 107.7 ± 2.3)*
Hum Genet (2011) 129:129–139 135
123Associations between rs1130214 and the STRRIDE
Study for glucose-stimulated glucose-release (Sg)
levels
The STRRIDE Study is a cohort of insulin-resistant middle-
aged adults. The H2 haplotype (the T allele of rs1130214)
was associated with higher Sg in European American males
(TT, p = 0.021) (Table 10). This is consistent with the
other cohorts and H2 associations with insulin resistance
phenotypes and even protection against metabolic syn-
drome, which often follows the development of insulin
resistance. There were no signiﬁcant associations (denoted
as NS) with any other group of this cohort (Table 10).
Discussion
We deﬁned the haplotype structure of the AKT1 gene and
studied 12 representative SNPs in a young adult population
to identify genetic predispositions to endophenotypes of
metabolic syndrome. We identiﬁed a relatively small 12 kb
haplotype, deﬁned by the SNPs rs1130214, rs10141867
and rs33925946, which are in very strong linkage dis-
equilibrium in all populations studied. In the young adult
population (FAMUSS Study), the ancestral haplotype of
the 12 kb region (H1; tagged by rs1130214) was associated
with higher fasting glucose in females (average age
24 years), suggesting that the 12 kb haplotype is associated
with insulin resistance. We validated this ﬁnding ﬁrst in an
older and more heterogeneous Native American population
(SHS; average age 56 years), where H1 had higher fasting
serum glucose, higher serum insulin, and a higher HOMA
value in males, all consistent with association with insulin
resistance. Although we originally identiﬁed an association
with fasting glucose levels in the FAMUSS females, we did
not see this same association in the older females of the
SHS or Health ABC. We then studied a cohort of aged
African-American and European American (Health ABC;
average age 73 years), and also found evidence for asso-
ciation with insulin resistance, where men with H1 showed
higher fasting glucose.
Insulin resistance is one of the ﬁve key endophenotypes
associated with T2D, and the precursor state of metabolic
syndrome. The diagnosis of metabolic syndrome is made
when a subject shows increased visceral adiposity, and two
additional threshold phenotypes [increased insulin resis-
tance, increased blood pressure, increased triglycerides
(TGs), and low HDL serum levels]. Insulin resistance is a
complex physiological and biochemical phenotype
involving responses to increased serum glucose by the
pancreas, muscle, and liver. The individual components of
pancreas, muscle and liver can be resolved by an IVGTT.
We studied the association of the 12 kb upstream haplo-
type with the IVGTT data from STRRIDE subjects with
features of metabolic syndrome, and found evidence for
association with the Sg phenotype. Thus, four distinct
cohorts all validated association of the upstream AKT1
12 kb haplotype (H1) with increased insulin resistance; H2
associates with decreased insulin resistance.
Given the association of the 12 kb AKT1 upstream
haplotype with measures of insulin resistance in four
cohorts, we queried the association of the same haplotype
with metabolic syndrome diagnosis. It is important to note
that the H1 haplotype is the more common haplotype in all
populations, and thus associations of a common haplotype
with a rare trait become more challenging statistically. Of
the four populations studied, only one was felt to be ade-
quate for testing of metabolic syndrome associations,
namely the Health ABC Study. The FAMUSS Study
population was too young to have an appreciable incidence
of metabolic syndrome. The Strong Heart Study was quite
heterogeneous in age and showed a very high incidence of
many comorbidities associated with metabolic syndrome.
The STRRIDE Study was a non-population based study,
where participants were recruited based upon having fea-
tures of metabolic syndrome. However, the Health ABC
Study was of large size (n = 3,000), with tightly restricted
age (73.6 years), with metabolic syndrome as a key focus
of the study. Genotyping of the upstream haplotype in
Health ABC showed a very strong association with meta-
bolic syndrome diagnosis (Table 9). Homozygotes for the
ancestral H1 haplotype (GG) had double the risk of
metabolic syndrome compared to those homozygous for
the less common H2 haplotype (TT). This association was
retained when the population was stratiﬁed by sex and
ethnicity.
Along with protection from metabolic syndrome, the
AKT1 H2 haplotype was associated with higher values of
TGs in males in the SHS. This result is counterintuitive to
the association of lower 2-h glucose, lower fasting insulin,
and lower HOMA value. A current issue in genetics is the
extension of associated loci discovered using genome-wide
association studies (GWAS) in European ancestry to non-
European individuals (Murray et al. 2010; Teslovich et al.
2010). For example, a recent study (Murray et al. 2010)
examined SNPs for asthma risk in two African ancestry
Table 10 The T allele of rs1130214 was associated with higher Sg in
the STRRIDE cohort
Phenotype Cohort F test p value
Baseline Sg Caucasian males 4.06 0.021*
African-American males 1.01 NS
Caucasian females 1.28 NS
African-American females 2.97 NS
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123groups that were located near a gene encoding ORMDL3
(17q21) that was identiﬁed for asthma risk in individuals
with European-descent (Moffatt et al. 2007). The SNPs
near the ORMDL3 gene did not replicate risk for asthma in
the African ancestry groups (Murray et al. 2010). Con-
currently, another study focusing on the genetics of blood
lipids found 24 of 27 SNPs replicated for TG values
between European-descent and South Asians, a replication
of 26 of 28 SNPs for TG values in East Asians, and a
replication of 24 of 30 SNPs for TG values in African-
Americans (Teslovich et al. 2010). These results speak of
the difﬁculty that exists in understanding genetic variation
and its relationship to different phenotypes in different
ethnic groups. The higher TG values associated with H2
haplotype in the SHS may be due an interaction with the
lack of access to medications that can control lipids (Stern
1998) and genotype. Finally, there is an ongoing unfavor-
able increase in the prevalence of hypertension, low HDL,
and diabetes mellitus in the aging survivors of the SHS and
this will likely lead to further increases in CVD morbidity
and mortality. This interaction between AKT1 H2 and TG
will need to be further explored in additional populations.
To our knowledge, the 12 kb haplotype described here is
one of the strongest candidate gene studies for either
insulin resistance or a metabolic syndrome diagnosis
identiﬁed to date. In another report, we report function for
all the SNPs in the associated haplotype (Harmon et al.
2010, submitted). In future studies, we will examine how
this AKT1 haplotype impacts the effect on insulin resis-
tance when combined with the numerous reported genome-
wide association studies (GWAS) of isolated insulin
resistance (Lyssenko et al. 2009), insulin response (Rich
et al. 2009), fasting glucose (Bouatia-Naji et al. 2008;
Dupuis et al. 2010; Prokopenko et al. 2009), glucose
response (Saxena et al. 2010), and GWAS studies of the
fully morbid T2D diagnosis (Wellcome Trust Case Control
Consortium 2007; Rung et al. 2009; Saxena et al. 2007;
Scott et al. 2007; Zeggini et al. 2008).
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Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
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